Medication for Chilblains
Nifedipine 20-60 mg daily is the first-line pharmacologic treatment for chilblains, with moderate evidence supporting its efficacy in reducing healing time and preventing new lesions. 1, 2
First-Line Pharmacologic Treatment
Nifedipine (calcium channel blocker) is the most evidence-based option for moderate to severe chilblains:
- Dosing: 20-60 mg daily 2
- Mechanism: Acts as a vasodilator, increasing cutaneous blood flow and reducing dermal edema 2, 3
- Evidence: Double-blind placebo-controlled trials demonstrate significant reduction in time to clearance of existing lesions, prevention of new chilblains, and reduction in pain/irritation 2
- Additional effects: Down-regulates inflammatory pathways (TNF-α, IL-6, IL-1β) and TRP family proteins involved in cold-induced inflammation 3
Second-Line Treatment
Pentoxifylline 400 mg three times daily is an effective alternative with strong evidence:
- Duration: 3 weeks of treatment 4
- Evidence: Double-blind placebo-controlled trial (n=110) showed significantly better therapeutic response compared to placebo at 7,14, and 21 days (p<0.05) 4
- Safety: No side effects reported in clinical trials 4
- Strength of recommendation: Moderate evidence supports use in severe or refractory cases 1
Adjunctive Topical Therapies
Topical corticosteroids (high-potency) may provide symptomatic relief:
- Application: Betamethasone or clobetasol propionate applied to affected areas 5
- Limitation: Effectiveness not confirmed by randomized trials, but widely used in clinical practice 5
Topical glyceryl trinitrate (GTN) has limited evidence but may be considered:
- Mechanism: Local vasodilation 1
- Evidence: Inadequate evidence compared to placebo in controlled trials 1
Treatments With Insufficient Evidence
The following have been studied but lack robust evidence:
- Tadalafil: Some positive results but insufficient data 1
- Topical minoxidil: Nonsignificant results versus placebo 1
- Diltiazem: Limited evidence 1
- Vitamin D: Inadequate evidence 1
- Hydrochloroquine: Positive effects only in small numbers 5
Secondary Chilblains (Associated With Autoimmune Disease)
For chilblains associated with lupus erythematosus or inflammatory arthritis:
- Methotrexate 7.5-25 mg weekly: Effective for cutaneous lupus including chilblain lupus, with 98% showing significant decline in disease activity by 8 weeks 6
- Systemic corticosteroids: May be necessary for secondary chilblains with inflammatory arthritis, showing excellent clinical response 7
- Disease-modifying drugs: Immunosuppression is the cornerstone for secondary chilblains, superior to symptomatic treatment alone 7
Clinical Algorithm
- Mild cases: Conservative management with warming measures alone
- Moderate to severe primary chilblains: Start nifedipine 20-60 mg daily 2
- Refractory or contraindication to nifedipine: Switch to pentoxifylline 400 mg TID for 3 weeks 4
- Secondary chilblains (with autoimmune features): Screen for underlying disease; consider methotrexate or systemic immunosuppression 6, 7
- Adjunctive therapy: Add high-potency topical corticosteroids for symptomatic relief 5
Important Caveats
- Natural course: Chilblains spontaneously remit and relapse, making treatment efficacy difficult to assess without controlled trials 1
- Cardiovascular considerations: Nifedipine may cause hypotension, peripheral edema, or headache; monitor blood pressure 2
- Screen for secondary causes: Always evaluate for underlying autoimmune disease (SLE, inflammatory arthritis, vasculitis) before labeling as primary chilblains 7, 6
- Smoking cessation: Essential as smoking exacerbates vasospasm 5